JP2023500953A5 - - Google Patents

Info

Publication number
JP2023500953A5
JP2023500953A5 JP2022526720A JP2022526720A JP2023500953A5 JP 2023500953 A5 JP2023500953 A5 JP 2023500953A5 JP 2022526720 A JP2022526720 A JP 2022526720A JP 2022526720 A JP2022526720 A JP 2022526720A JP 2023500953 A5 JP2023500953 A5 JP 2023500953A5
Authority
JP
Japan
Prior art keywords
polypeptide
vwf
erythrocyte
pharmaceutical composition
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022526720A
Other languages
English (en)
Japanese (ja)
Other versions
JP7680442B2 (ja
JP2023500953A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/081698 external-priority patent/WO2021094344A1/en
Publication of JP2023500953A publication Critical patent/JP2023500953A/ja
Publication of JP2023500953A5 publication Critical patent/JP2023500953A5/ja
Application granted granted Critical
Publication of JP7680442B2 publication Critical patent/JP7680442B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022526720A 2019-11-11 2020-11-11 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド Active JP7680442B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19208259 2019-11-11
EP19208259.2 2019-11-11
PCT/EP2020/081698 WO2021094344A1 (en) 2019-11-11 2020-11-11 Polypeptides for inducing tolerance to factor viii

Publications (3)

Publication Number Publication Date
JP2023500953A JP2023500953A (ja) 2023-01-11
JP2023500953A5 true JP2023500953A5 (https=) 2023-11-17
JP7680442B2 JP7680442B2 (ja) 2025-05-20

Family

ID=68531414

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526720A Active JP7680442B2 (ja) 2019-11-11 2020-11-11 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド

Country Status (4)

Country Link
US (1) US20220348637A1 (https=)
EP (1) EP4058049A1 (https=)
JP (1) JP7680442B2 (https=)
WO (1) WO2021094344A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026068504A2 (en) 2024-09-24 2026-04-02 The University Of Bristol Novel protein conjugates

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
DE69534265T2 (de) 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
EP2114458B1 (en) 2006-12-27 2014-02-26 Nektar Therapeutics Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
CN101730707B (zh) 2007-07-11 2014-12-17 诺沃-诺迪斯克有限公司 使用混合式或多模式树脂来纯化因子ⅷ
KR20100095441A (ko) 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
US20100099616A1 (en) 2008-10-17 2010-04-22 Baxter International Inc. Modified blood factors comprising a low degree of water soluble polymer
JP5365813B2 (ja) 2009-01-28 2013-12-11 日本電気株式会社 不揮発ロジック回路
ES2401965T3 (es) 2009-02-19 2013-04-25 Novo Nordisk A/S Modificación de Factor VIII
ES2427627T3 (es) 2009-04-06 2013-10-31 Novo Nordisk A/S Entrega dirigida de proteínas de Factor VIII a plaquetas
WO2011060242A2 (en) 2009-11-13 2011-05-19 Talecris Biotherapeutics, Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
JP2013519699A (ja) 2010-02-16 2013-05-30 ノヴォ ノルディスク アー／エス 因子ｖｉｉｉ融合タンパク質
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
CN102812039B (zh) 2010-02-16 2016-01-20 诺沃—诺迪斯克有限公司 缀合蛋白质
CN102939110A (zh) 2010-04-21 2013-02-20 诺沃—诺迪斯克有限公司 蛋白质的选择性修饰
JP2013532176A (ja) 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
EP2603520A4 (en) 2010-08-10 2014-02-19 Ecole Polytech ERYTHROCYTE BINDING THERAPEUTICS
WO2013121296A1 (en) 2012-02-15 2013-08-22 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
WO2014135528A1 (en) 2013-03-04 2014-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and immunoconjugates and uses thereof
CN105452289A (zh) 2013-06-12 2016-03-30 诺和诺德股份有限公司 适用于治疗血友病的化合物
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
DK3400002T3 (da) * 2016-01-07 2022-04-11 CSL Behring Lengnau AG Muteret, trunkeret von willebrand faktor
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
US11104718B2 (en) 2016-11-16 2021-08-31 Bayer Healthcare Llc Red blood cell targeted factor VIII and method of using the same
ES2966835T3 (es) * 2017-06-22 2024-04-24 CSL Behring Lengnau AG Modulación de la inmunogenicidad del FVIII por VWF truncado
JP7278270B2 (ja) 2017-10-20 2023-05-19 シーエスエル、リミテッド 方法

Similar Documents

Publication Publication Date Title
EP3844181B1 (en) Multi-chain chimeric polypeptides and uses thereof
EP3844182B1 (en) Single-chain and multi-chain chimeric polypeptides and uses thereof
AU2020294797B2 (en) Multi-chain chimeric polypeptides and uses thereof
CN103180339B (zh) 具有改善的稳定性的基于纤连蛋白的支架蛋白质
ES2356896T3 (es) Anticuerpos humanizados contra icam-1, su producción y usos.
JP2017160222A5 (https=)
JP2023103368A5 (https=)
JP2024533311A5 (https=)
JP2020515280A5 (https=)
WO2022022718A1 (zh) 抗cd133的单链抗体及其在制备治疗肿瘤的药物中的用途
JP2019536426A5 (https=)
JP2023553697A5 (https=)
JP2004508828A (ja) 標的−特異的プロドラッグとしての使用のための抗体サイトカイン−サイトカインインヒビター（セレクトカイン）からの融合タンパク質
JP2020509737A5 (https=)
WO2024008110A1 (zh) 抗ccr8抗体及其应用
WO2022126687A1 (zh) 一种抗Claudin18.2的抗原结合片段、抗体及其应用
WO2026007560A1 (zh) 一种靶向成纤维活化蛋白α的纳米抗体及其应用
CN112048018A (zh) 一种嵌合t细胞生长因子及其应用
JP2023500953A5 (https=)
JP2024023268A5 (https=)
Qin et al. Screening and anti‐glioma activity of Chiloscyllium plagiosum anti‐human IL‐13Rα2 single‐domain antibody
JP2024532760A (ja) 多重鎖キメラポリペプチド及び肝疾患の治療におけるその使用
WO2023039242A2 (en) Multivalent interferon particles compositions and methods of use
JP2020535832A (ja) マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法
CN106928365B (zh) 一种FAP纳米抗体Nb36